Educating Psychiatry Trainees on Social Determinants of Health
A Montefiore residency director explains the impact of engaging with communities to improve mental health care capability.
Yoga vs Antidepressants: Defining Workplace Burnout Over Mental Health Issues
Montefiore's Carol A. Bernstein, MD, discusses the role of psychiatry specialists in discerning their colleagues' need for mental health care or resolutions to burnout.
Sleep Pharmacotherapy, Melatonin, and the Link to Substance Use Disorders
Gina Poe, PhD, discusses the potential role of beta blockers in treating psychiatric illness-related sleep, as well as the specific benefit of melatonin.
Gina Poe, PhD: How Psychiatric Diseases Impact Sleep Health
The UCLA-based investigator discusses the unique impact of PTSD on patients' sleep stages, and how they can limit their insomnia.
Nora D. Volkow, MD: The Pain Crisis, and Optimizing Addiction Care Delivery
The director of NIDA discusses the interplay of substance use disorder and pain in patients, as well as means to assure patients are receiving evidenced-based treatment.
Identifying and Treating Adolescent Borderline Personality Disorder
Lois Choi-Kain, MD, MEd, discusses the unique presentations of disease and burdens of care that impact younger patients with BPD.
The Psychiatry Blueprint to Retaining Diverse Trainees, Treating Disparity
The modern psychiatrist may play many roles, including as a mentor and a facilitator to social-based support.
Nora D. Volkow, MD: Advancing Clinical Research for Treating Use Disorders
The NIDA director reviews neuromodulation's potential role in treating patients with multiple use disorders, and the importance of patient feedback in shaping clinical research.
Challenges in Psychiatry Patient Disparities and Caregiver Representation
Rachel Talley, MD, discusses the industry-level changes needed to trainee recruitment and retention to create a psychiatry field more representative of its patient population.
The Ketamine & Esketamine Care Teams, and Necessary Monitoring
With administration strategies for the psychiatric anesthetic drug well established, clinicians have interest in accumulating long-term data and other potential indications.
Blood Biomarkers, Aducanumab and Setting Precedent for Dementia Care Advances
Brent Forester, MD, MSc, discusses the confluence of biomarker and disease-targeting therapy in Alzheimer's, and the need to appropriately introduce these tools.
Nora D. Volkow, MD: Combating COVID-Era Issues in Substance Use Disorder
The director of NIDA discusses the unprecedented impact of the pandemic on overdose deaths—and how substance use disorder care may still reach greater capability when all is said and done.
The Challenges to Identifying Dementia, Alzheimer-Risk Patients
Dementia and Alzheimer's disease cases are anticipated to boom in coming decades. One expert stressed the need for improved screening and facilitation of care at the earliest stages and signs.
Guiding Appropriate Ketamine, Esketamine Use in Psychiatry
The lead author of treatment recommendations weighs in on their current use and future research.
How Evolving Psychiatric Definitions Set the Tone for Care
Amid significant psychotherapy innovation and consideration to broader aspects of mental illness definition, Jonathan Alpert, MD, PhD, emphasizes the need for improved clinical trial standards.
Adjunctive Cariprazine with Antidepressants Benefits Adult Major Depressive Disorder
New phase 3 data presented at APA 2022 support the agent as an adjunctive in older patients without benefit from monotherapy antidepressant medication.
How Mental Illness Definitions Are Still Being Uncovered and Refined
Montefiore psychiatry chair Jonathan Alpert, MD, PhD, discusses suggested updates to the DSM-5—with consideration to social determinants and patient-reported functioning.
The Pediatric Disaster Psychiatry Care Team
Linda Chokroverty, MD, discusses the significance of timing, communication and care coordination when children are affected by disasters or trauma.
Understanding Socially-Determined Mental Health and the Impact of COVID-19
APA president-elect Rebecca W. Brendel, MD, JD, discusses the need to prepare for a "twin mental health pandemic" while continuing to appropriately facilitate innovations in psychiatric care.
Zuranolone Benefits Major Depression, Postpartum Depression in Clinical Program
Anita Clayton, MD, reviews the available phase 2 and 3 clinical data for the novel, once-daily oral investigative drug.
The Need for Disaster Psychiatry Care
Linda Chokroverty, MD, discusses the role psychiatrists play in managing the mental health effects of disasters, and how children specifically may be impacted.
Eco-Anxiety and Contributing Mental Health Factors Among BIPOC
A pair of psychiatrists discuss how climate change and other social determinants of health are affecting the mental wellbeing of indigenous people.
Who Makes Up the Modern Dementia Care Team?
It takes even more than a village to provide the comprehensive care needed for aging, neurocognitive patients, says Rajesh R. Tampi, MD, MS.
Second-Generation Long-Acting Injectables Significantly Improve Long-Term Severe Schizophrenia Outcomes
A 6-year mirror analysis of risperidone, once-monthly paliperidone palmitate or once-monthly aripiprazole concludes suggesting the regimens may serve as an alternative to clozapine.
The Developing Dementia Definition, Treatment Field
Rajesh R. Tampi, MD, MS, discusses the evolved definition of dementia as a cognitive disorder, and how its spectrum of symptoms impact clinical development.
Drop in Suicides Won't Result in Complacency in Psychiatry
A recent JAMA study shows a decrease in suicide deaths between 2019-2020, despite a 17% overall increase in mortality.
Christoph Correll, MD: An Overview of Schizophrenia Treatments
Approximately 30% of schizophrenia patients do not respond to their first treatment.
Children with ADHD May Benefit from Dextroamphetamine Transdermal Treatment
Andrew J. Cutler, MD discusses new research into the efficacy and safety of a D-ATS treatment in children with ADHD.
Anum Baig, MD: The Future of Schizophrenia Treatment
Clozapine is considered the gold standard of schizophrenia treatment.
Anum Baig, MD: Overcoming Barriers in Schizophrenia Care
Education could be the best resource in increasing prescription rates for clozapine.
